There is research on this stock available only to PRO subscribers.
- Ruthigen is developing a low-tech, common sense solution to meet a significant medical need.
- The indication allows the company to move quickly, with IND to NDA taking only 4 years, according to company guidance.
- The current market cap significantly undervalues Ruthigen if any signs of efficacy are observed in Phase I/II.
- Ruthigen's IPO provides strong investment opportunity based on relative valuations and addressing unmet market need with potential multi-billion dollar market.
- Tetraphase Pharmaceuticals in turn presents a short opportunity as a potentially inferior comp a year ahead of Ruthigen with >10x the market cap.
- Long RTGN and short TTPH is set up to be an ideal pair trade with upside on both ends and decreased market exposure.